Anticoagulation after valve replacement: A multicenter retrospective study

Artificial Organs

Volumn 23, Issue 2, 1999, Pages 199-203

  Kudo, Tatsuhiko ^a   Kawase, Mitsuhiko ^b   Kawada, Shiaki ^c   Kurosawa, Hiromi ^d   Koyanagi, Hitoshi ^e   Takeuchi, Yasuo ^f   Hosoda, Yasuyuki ^g   Wanibuchi, Yasuhiko ^h  

^a TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^b SAKAKIBARA HEART INSTITUTE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f Kanto Teishin Hospital   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Anticoagulant therapy; Mechanical valve; Prothrombin time international normalized ratio; Tokyo Area Study trial

Indexed keywords

CARDIOVASCULAR SURGERY; VALVES (MECHANICAL);

ANTI-COAGULATION; ANTICOAGULANT THERAPY; BLEEDINGS; CARDIAC VALVES; INTERNATIONAL NORMALIZED RATIOS; MECHANICAL VALVES; PROTHROMBIN TIME; PROTHROMBIN TIME INTERNATIONAL NORMALIZED RATIO; TOKYO AREA STUDY TRIAL; VALVE REPLACEMENT;

HEART;

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIPYRIDAMOLE; SULFINPYRAZONE; TICLOPIDINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL RESEARCH; FEMALE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOEMBOLISM;

EID: 0033041861     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06110.x     Document Type: Article

References (12)

1. 1. Uetsuka Y, Hosoda S, Aosaki M, Iwade K, Koyanagi H, Ohki K, Hokari T, Inoue M, Akiyama E, Kitada M. Clinical significance of thrombotest and PT-INR in monitoring oral anticoagulant therapy. Jpn J Thromb Hemost 1992;3:123-30.
2. 2. Chikada M, Yagyu K, Kotsuka Y, Furuse A. Anticoagulant therapy after mechanical heart valve replacement with special reference to INR. Kyobu Geka 1994;47:895-8.
3. 3. Hirsh I. Oral anticoagulant therapy - Urgent need for standardization. Circulation 1992;86:1332-5.
4. 4. Barwolf CG, Acar J, Burckhardt D. Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Dis 1993;2:398-410.
5. 5. Cannegieter SC, Rosendall FR, Wintzen AR, Van der Meer, Vanderbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
6. 6. Eberlein U, von der Emde J, Rein J, Esperer HD. Thromboembolic and bleeding complications after mitral valve replacement. Eur J Cardiothorac Surg 1990;4:605-12.
7. 7. Horstkotte D, Schulte HD, Bircks W, Stauer BE. Lower intensity anticoagulation therapy results in lower complications rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994;107:1136-45.
8. 8. Wilson DB, Dunn MI, Hassanein K. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 1991;100: 1553-7.
9. 9. Cortelazzo S, Finazzi G, Galli M, Remuzzi A, Parenzan L, Barbui T. Thromboembolic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69:316-20.
10. 10. Edmunds LH. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987;44:430-45.
11. 11. Shimodaira H, Takahashi K, Kano K, Matsumoto Y, Uchida Y, Kudo T. Enhancement of anticoagulant action by warfarinbenzbromarone interaction. J Clin Pharmacol 1996;36:168-74.
12. 12. Cannegieter SC, Rosendall FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prosthesis. Circulation 1994;89:635-41.